Bicalutamide: Crossover not realistic [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2019-10-07 14:59 (722 d 12:44 ago) – Posting: # 20674
Views: 1,769

Hi Udaya,

» We need clarification on study design of BE of Bicalutamide 50mg tablets since, its long half life is around 150 hours and most of the available literatures have shown as parallel BE study with last time point as 672 hours and two-way cross over study with last time point as 672 hours.

I can only give what I found in my study: Parallel, 60 subjects (30 per arm), 2 dropouts. We aimed at very similar demographics, e.g., the median body weights differed only ½ kg between groups. ;-)
Sampling: Pre-dose, 1, 2, 4, 6, 8, 10, 12, 18, 24, 30, 36, 42, 48, 72, 168, 336, 504, and 672 hours. End of hospitalization 48 hours.
Bioanalytics: LC/MS-MS, LLOQ 10 ng/mL for R(–) bicalutamide and 5 ng/mL for S(+) bicalutamide. ULOQ 1 µg/mL R(–) and 100 ng/mL (S+).
R(–) was confirmatory and S(+) exploratory. The CVs were ~21% for AUC and ~10% for Cmax (yes, lower than AUC…). x̃ of tmax was 36 h for both treatments with some subjects having tmax at 72 h. Given such late tmax-values I don’t expect that regulators will accept pAUC0–72 as the primary metric of extent of absorption (instead of AUC0–t). I suggest to add ad least sampling at 96 h.

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,704 posts in 4,538 threads, 1,541 registered users;
online 4 (0 registered, 4 guests [including 2 identified bots]).
Forum time: Wednesday 03:44 CEST (Europe/Vienna)

It has yet to be proven
that intelligence has any survival value.    Arthur C. Clarke

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz